Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF
The Journal of Clinical Endocrinology & Metabolism · 21.01.2025 · 110 (2) · e456-e460
DOI: 10.1210/clinem/dgae168 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 14.03.2024. Verfasst von Marco Mouanness und 1 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Endocrinology and Infertility, Rejuvenating Fertility Center, New York, NY 10027, USA. Hauptthemen laut MEDLINE: Gonadotropin-Releasing Hormone, Hormone Antagonists, Ovulation Inhibition. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
The injectable gonadotropin-releasing hormone (GnRH) antagonists have traditionally been used for ovulation suppression during controlled ovarian hyperstimulation for in vitro fertilization (IVF), leading to increased painful daily injections and cost. The use of the oral GnRH antagonist elagolix for ovulation suppression in IVF has not been studied.
Methods
This retrospective cohort study of patients undergoing IVF who received either oral elagolix 50 mg every other day or ganirelix/cetrotide injection daily for ovulation suppression during controlled ovarian hyperstimulation included 269 patients, 173 in the elagolix group and 96 in the ganirelix/cetrotide group. The main outcome was the suppression of luteinizing hormone (LH) blood levels, reflecting ovulation suppression.
Results
Age, body mass index, anti-Müllerian hormone, baseline follicle-stimulating hormone, antral follicles count, dose of medications used, number of days of ovarian stimulation, and peak estradiol (E2) levels were similar in both groups. When blood LH and E2 levels were measured before intake and the day after intake of either elagolix or ganirelix/cetrotide, both groups had significant and similar drop in LH levels and increase in E2 levels. When comparing IVF cycle outcomes in both groups, the number of oocytes retrieved, number of mature oocytes, fertilization rate, blastocyst formation rate, euploidy rate, and endometrial lining thickness at the time of the trigger were all similar.
Conclusion
Oral GnRH antagonist, a much cheaper and less invasive medication that is used at a lower frequency, showed comparable ovulation suppression to the costly injectable GnRH antagonist. Further studies are required to evaluate the effect of oral GnRH antagonist on endometrial lining receptivity and pregnancy outcomes, especially when using fresh embryo transfer IVF protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Reproductive Endocrinology and Infertility, Rejuvenating Fertility Center, New York, NY 10027, USA.
- Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA.
- Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY 10019, USA.
ORCID-Profile: Zaher Merhi
Zitieren
APA
Mouanness, M., & Merhi, Z. (2025). Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF. The Journal of Clinical Endocrinology & Metabolism, 110(2), e456-e460. https://doi.org/10.1210/clinem/dgae168
Vancouver
Mouanness M, Merhi Z. Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF. The Journal of Clinical Endocrinology & Metabolism. 2025;110(2):e456-e460. doi:10.1210/clinem/dgae168
BibTeX
@article{Mouanness2025,
author = {Mouanness, Marco and Merhi, Zaher},
title = {Elagolix Represents a Less Invasive and Cheaper Option Than Injectable GnRH Antagonist for Ovulation Suppression in IVF},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {2},
pages = {e456--e460},
doi = {10.1210/clinem/dgae168}
}
EUVIMED